Cargando…

M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer

BACKGROUND: The immunological microenvironment of primary high-grade serous carcinomas (HGSCs) has a major impact on disease outcome. Conversely, little is known on the microenvironment of metastatic HGSCs and its potential influence on patient survival. Here, we explore the clinical relevance of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hensler, Michal, Kasikova, Lenka, Fiser, Karel, Rakova, Jana, Skapa, Petr, Laco, Jan, Lanickova, Tereza, Pecen, Ladislav, Truxova, Iva, Vosahlikova, Sarka, Moserova, Irena, Praznovec, Ivan, Drochytek, Vit, Rehackova, Martina, Brtnicky, Tomas, Rob, Lukas, Benes, Vladimir, Pistolic, Jelena, Sojka, Ludek, Ryska, Ales, Sautes-Fridman, Catherine, Fridman, Wolf Herve, Galluzzi, Lorenzo, Spisek, Radek, Fucikova, Jitka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443306/
https://www.ncbi.nlm.nih.gov/pubmed/32819974
http://dx.doi.org/10.1136/jitc-2020-000979
_version_ 1783573609010167808
author Hensler, Michal
Kasikova, Lenka
Fiser, Karel
Rakova, Jana
Skapa, Petr
Laco, Jan
Lanickova, Tereza
Pecen, Ladislav
Truxova, Iva
Vosahlikova, Sarka
Moserova, Irena
Praznovec, Ivan
Drochytek, Vit
Rehackova, Martina
Brtnicky, Tomas
Rob, Lukas
Benes, Vladimir
Pistolic, Jelena
Sojka, Ludek
Ryska, Ales
Sautes-Fridman, Catherine
Fridman, Wolf Herve
Galluzzi, Lorenzo
Spisek, Radek
Fucikova, Jitka
author_facet Hensler, Michal
Kasikova, Lenka
Fiser, Karel
Rakova, Jana
Skapa, Petr
Laco, Jan
Lanickova, Tereza
Pecen, Ladislav
Truxova, Iva
Vosahlikova, Sarka
Moserova, Irena
Praznovec, Ivan
Drochytek, Vit
Rehackova, Martina
Brtnicky, Tomas
Rob, Lukas
Benes, Vladimir
Pistolic, Jelena
Sojka, Ludek
Ryska, Ales
Sautes-Fridman, Catherine
Fridman, Wolf Herve
Galluzzi, Lorenzo
Spisek, Radek
Fucikova, Jitka
author_sort Hensler, Michal
collection PubMed
description BACKGROUND: The immunological microenvironment of primary high-grade serous carcinomas (HGSCs) has a major impact on disease outcome. Conversely, little is known on the microenvironment of metastatic HGSCs and its potential influence on patient survival. Here, we explore the clinical relevance of the immunological configuration of HGSC metastases. METHODS: RNA sequencing was employed on 24 paired primary tumor microenvironment (P-TME) and metastatic tumor microenvironment (M-TME) chemotherapy-naive HGSC samples. Immunohistochemistry was used to evaluate infiltration by CD8(+) T cells, CD20(+) B cells, DC-LAMP(+) (lysosomal-associated membrane protein 3) dendritic cells (DCs), NKp46(+) (natural killer) cells and CD68(+)CD163(+) M2-like tumor-associated macrophages (TAMs), abundance of PD-1(+) (programmed cell death 1), LAG-3(+) (lymphocyte-activating gene 3) cells, and PD-L1 (programmed death ligand 1) expression in 80 samples. Flow cytometry was used for functional assessments on freshly resected HGSC samples. RESULTS: 1468 genes were differentially expressed in the P-TME versus M-TME of HGSCs, the latter displaying signatures of extracellular matrix remodeling and immune infiltration. M-TME infiltration by immune effector cells had little impact on patient survival. Accordingly, M-TME-infiltrating T cells were functionally impaired, but not upon checkpoint activation. Conversely, cytokine signaling in favor of M2-like TAMs activity appeared to underlie inhibited immunity in the M-TME and poor disease outcome. CONCLUSIONS: Immunosuppressive M2-like TAM infiltrating metastatic sites limit clinically relevant immune responses against HGSCs.
format Online
Article
Text
id pubmed-7443306
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74433062020-08-28 M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer Hensler, Michal Kasikova, Lenka Fiser, Karel Rakova, Jana Skapa, Petr Laco, Jan Lanickova, Tereza Pecen, Ladislav Truxova, Iva Vosahlikova, Sarka Moserova, Irena Praznovec, Ivan Drochytek, Vit Rehackova, Martina Brtnicky, Tomas Rob, Lukas Benes, Vladimir Pistolic, Jelena Sojka, Ludek Ryska, Ales Sautes-Fridman, Catherine Fridman, Wolf Herve Galluzzi, Lorenzo Spisek, Radek Fucikova, Jitka J Immunother Cancer Immunotherapy Biomarkers BACKGROUND: The immunological microenvironment of primary high-grade serous carcinomas (HGSCs) has a major impact on disease outcome. Conversely, little is known on the microenvironment of metastatic HGSCs and its potential influence on patient survival. Here, we explore the clinical relevance of the immunological configuration of HGSC metastases. METHODS: RNA sequencing was employed on 24 paired primary tumor microenvironment (P-TME) and metastatic tumor microenvironment (M-TME) chemotherapy-naive HGSC samples. Immunohistochemistry was used to evaluate infiltration by CD8(+) T cells, CD20(+) B cells, DC-LAMP(+) (lysosomal-associated membrane protein 3) dendritic cells (DCs), NKp46(+) (natural killer) cells and CD68(+)CD163(+) M2-like tumor-associated macrophages (TAMs), abundance of PD-1(+) (programmed cell death 1), LAG-3(+) (lymphocyte-activating gene 3) cells, and PD-L1 (programmed death ligand 1) expression in 80 samples. Flow cytometry was used for functional assessments on freshly resected HGSC samples. RESULTS: 1468 genes were differentially expressed in the P-TME versus M-TME of HGSCs, the latter displaying signatures of extracellular matrix remodeling and immune infiltration. M-TME infiltration by immune effector cells had little impact on patient survival. Accordingly, M-TME-infiltrating T cells were functionally impaired, but not upon checkpoint activation. Conversely, cytokine signaling in favor of M2-like TAMs activity appeared to underlie inhibited immunity in the M-TME and poor disease outcome. CONCLUSIONS: Immunosuppressive M2-like TAM infiltrating metastatic sites limit clinically relevant immune responses against HGSCs. BMJ Publishing Group 2020-08-20 /pmc/articles/PMC7443306/ /pubmed/32819974 http://dx.doi.org/10.1136/jitc-2020-000979 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Immunotherapy Biomarkers
Hensler, Michal
Kasikova, Lenka
Fiser, Karel
Rakova, Jana
Skapa, Petr
Laco, Jan
Lanickova, Tereza
Pecen, Ladislav
Truxova, Iva
Vosahlikova, Sarka
Moserova, Irena
Praznovec, Ivan
Drochytek, Vit
Rehackova, Martina
Brtnicky, Tomas
Rob, Lukas
Benes, Vladimir
Pistolic, Jelena
Sojka, Ludek
Ryska, Ales
Sautes-Fridman, Catherine
Fridman, Wolf Herve
Galluzzi, Lorenzo
Spisek, Radek
Fucikova, Jitka
M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
title M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
title_full M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
title_fullStr M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
title_full_unstemmed M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
title_short M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
title_sort m2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
topic Immunotherapy Biomarkers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443306/
https://www.ncbi.nlm.nih.gov/pubmed/32819974
http://dx.doi.org/10.1136/jitc-2020-000979
work_keys_str_mv AT henslermichal m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT kasikovalenka m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT fiserkarel m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT rakovajana m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT skapapetr m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT lacojan m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT lanickovatereza m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT pecenladislav m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT truxovaiva m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT vosahlikovasarka m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT moserovairena m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT praznovecivan m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT drochytekvit m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT rehackovamartina m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT brtnickytomas m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT roblukas m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT benesvladimir m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT pistolicjelena m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT sojkaludek m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT ryskaales m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT sautesfridmancatherine m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT fridmanwolfherve m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT galluzzilorenzo m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT spisekradek m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer
AT fucikovajitka m2likemacrophagesdictateclinicallyrelevantimmunosuppressioninmetastaticovariancancer